Literature DB >> 2353671

Spironolactone in the management of congestive heart failure.

J E Muller1.   

Abstract

Although many new drugs useful in the treatment of congestive heart failure have been introduced during the past 25 years, spironolactone continues to have an important role in the management of this condition. Spironolactone adds to the activity of the thiazide and loop diuretics to enhance the elimination of sodium and water. Furthermore, unwanted electrolyte disturbances such as hypokalemia and hypomagnesemia, associated with the administration of other classes of diuretics, can be minimized with spironolactone.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2353671     DOI: 10.1016/0002-9149(90)91281-a

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  1 in total

1.  The p.Pro482Ala Variant in the CNNM2 Gene Causes Severe Hypomagnesemia Amenable to Treatment with Spironolactone.

Authors:  Ioannis Petrakis; Eleni Drosataki; Ioanna Stavrakaki; Kleio Dermitzaki; Dimitra Lygerou; Myrto Konidaki; Christos Pleros; Nikolaos Kroustalakis; Sevasti Maragkou; Ariadni Androvitsanea; Ioannis Stylianou; Ioannis Zaganas; Kostas Stylianou
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.